201 related articles for article (PubMed ID: 36513250)
1. Oxaliplatin-Resistant Hepatocellular Carcinoma Drives Immune Evasion Through PD-L1 Up-Regulation and PMN-Singular Recruitment.
Zhang F; Hu K; Liu W; Quan B; Li M; Lu S; Chen R; Ren Z; Yin X
Cell Mol Gastroenterol Hepatol; 2023; 15(3):573-591. PubMed ID: 36513250
[TBL] [Abstract][Full Text] [Related]
2. ID1 promotes hepatocellular carcinoma proliferation and confers chemoresistance to oxaliplatin by activating pentose phosphate pathway.
Yin X; Tang B; Li JH; Wang Y; Zhang L; Xie XY; Zhang BH; Qiu SJ; Wu WZ; Ren ZG
J Exp Clin Cancer Res; 2017 Nov; 36(1):166. PubMed ID: 29169374
[TBL] [Abstract][Full Text] [Related]
3. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
4. ID1 overexpression promotes HCC progression by amplifying the AURKA/Myc signaling pathway.
Wu M; Zhou Y; Fei C; Chen T; Yin X; Zhang L; Ren Z
Int J Oncol; 2020 Sep; 57(3):845-857. PubMed ID: 32705157
[TBL] [Abstract][Full Text] [Related]
5. Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy.
Zhou J; Liu M; Sun H; Feng Y; Xu L; Chan AWH; Tong JH; Wong J; Chong CCN; Lai PBS; Wang HK; Tsang SW; Goodwin T; Liu R; Huang L; Chen Z; Sung JJ; Chow KL; To KF; Cheng AS
Gut; 2018 May; 67(5):931-944. PubMed ID: 28939663
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy-induced recruitment of myeloid-derived suppressor cells abrogates efficacy of immune checkpoint blockade.
Kwong TT; Wong CH; Zhou JY; Cheng ASL; Sung JJY; Chan AWH; Chan SL
JHEP Rep; 2021 Apr; 3(2):100224. PubMed ID: 33604533
[TBL] [Abstract][Full Text] [Related]
7. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
8. LAIR1-mediated resistance of hepatocellular carcinoma cells to T cells through a GSK-3β/β-catenin/MYC/PD-L1 pathway.
Pan B; Ke X; Qiu J; Ye D; Zhang Z; Zhang X; Luo Y; Yao Y; Wu X; Wang X; Tang N
Cell Signal; 2024 Mar; 115():111039. PubMed ID: 38199599
[TBL] [Abstract][Full Text] [Related]
9. FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2.
Xie M; Lin Z; Ji X; Luo X; Zhang Z; Sun M; Chen X; Zhang B; Liang H; Liu D; Feng Y; Wang Y; Li Y; Liu B; Huang W; Xia L
J Hepatol; 2023 Jul; 79(1):109-125. PubMed ID: 36907560
[TBL] [Abstract][Full Text] [Related]
10. Fibrotic immune microenvironment remodeling mediates superior anti-tumor efficacy of a nano-PD-L1 trap in hepatocellular carcinoma.
Liu X; Zhou J; Wu H; Chen S; Zhang L; Tang W; Duan L; Wang Y; McCabe E; Hu M; Yu Z; Liu H; Choi CHJ; Sung JJ; Huang L; Liu R; Cheng AS
Mol Ther; 2023 Jan; 31(1):119-133. PubMed ID: 36146933
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of METTL5 inhibits the Myc pathway to downregulate PD-L1 expression and inhibits immune escape of hepatocellular carcinoma cells.
Xu W; Liu S; Zhang G; Liu J; Cao G
J Chemother; 2023 Sep; 35(5):455-464. PubMed ID: 36369791
[TBL] [Abstract][Full Text] [Related]
12. IL-1β-Induced Elevation of Solute Carrier Family 7 Member 11 Promotes Hepatocellular Carcinoma Metastasis Through Up-regulating Programmed Death Ligand 1 and Colony-Stimulating Factor 1.
He Q; Liu M; Huang W; Chen X; Zhang B; Zhang T; Wang Y; Liu D; Xie M; Ji X; Sun M; Tian D; Xia L
Hepatology; 2021 Dec; 74(6):3174-3193. PubMed ID: 34288020
[TBL] [Abstract][Full Text] [Related]
13. TP53/mTORC1-mediated bidirectional regulation of PD-L1 modulates immune evasion in hepatocellular carcinoma.
Yu J; Ling S; Hong J; Zhang L; Zhou W; Yin L; Xu S; Que Q; Wu Y; Zhan Q; Bao J; Xu N; Liu Y; Chen K; Wei X; Liu Z; Feng T; Zhou L; Xie H; Wang S; Liu J; Zheng S; Xu X
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38030304
[TBL] [Abstract][Full Text] [Related]
14. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma.
Liu M; Zhou J; Liu X; Feng Y; Yang W; Wu F; Cheung OK; Sun H; Zeng X; Tang W; Mok MTS; Wong J; Yeung PC; Lai PBS; Chen Z; Jin H; Chen J; Chan SL; Chan AWH; To KF; Sung JJY; Chen M; Cheng AS
Gut; 2020 Feb; 69(2):365-379. PubMed ID: 31076403
[TBL] [Abstract][Full Text] [Related]
15. Effect of Proton Therapy on Tumor Cell Killing and Immune Microenvironment for Hepatocellular Carcinoma.
Chen MF; Chen PT; Hsieh CC; Wang CC
Cells; 2023 Jan; 12(2):. PubMed ID: 36672266
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B virus-triggered PTEN/β-catenin/c-Myc signaling enhances PD-L1 expression to promote immune evasion.
Sun Y; Yu M; Qu M; Ma Y; Zheng D; Yue Y; Guo S; Tang L; Li G; Zheng W; Wang M; Guo D; Li C
Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G162-G173. PubMed ID: 31604033
[TBL] [Abstract][Full Text] [Related]
17. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
[TBL] [Abstract][Full Text] [Related]
18. Targeting the YB-1/PD-L1 Axis to Enhance Chemotherapy and Antitumor Immunity.
Tao Z; Ruan H; Sun L; Kuang D; Song Y; Wang Q; Wang T; Hao Y; Chen K
Cancer Immunol Res; 2019 Jul; 7(7):1135-1147. PubMed ID: 31113805
[TBL] [Abstract][Full Text] [Related]
19. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
20. PBK/TOPK promotes chemoresistance to oxaliplatin in hepatocellular carcinoma cells by regulating PTEN.
Cao H; Yang M; Yang Y; Fang J; Cui Y
Acta Biochim Biophys Sin (Shanghai); 2021 Apr; 53(5):584-592. PubMed ID: 33772548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
